Therapeutic Area: Oncology

The similarity of class II HLA genotypes defines patterns of autoreactivity in idiopathic bone marrow failure disorders

Pagliuca S, et al.
Blood
February 2022
immuneAccess
Authors and Affiliates
Simona Pagliuca 1,2, Carmelo Gurnari 1,3, Hassan Awada 1, Ashwin Kishtagari 1, Sunisa Kongkiatkamon 1, Laila Terkawi 1, Misam Zawit 1, Yihong Guan 1, Thomas LaFramboise 4, Babal K Jha 1, Bhumika J Patel 5, Betty K Hamilton 6, Navneet S Majhail 6, Sofie Lundgren 7,8, Satu Mustjoki 7,8,9, Yogen Saunthararajah 1, Valeria Visconte 1, Timothy A Chan 10, Chao-Yie Yang 11, Tobias L Lenz 12,13, Jaroslaw P Maciejewski 1; 1 Translational Hematology and Oncology Research Department, Cleveland Clinic, Cleveland, OH. 2 University of Paris, Paris, France. 3 Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy. 4 Department of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH. 5 Leukemia Program, Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH. 6 Blood and Marrow Transplant Program, Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH. 7 Hematology Research Unit Helsinki, University of Helsinki-Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland. 8 Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland. 9 ICAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland. 10 Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH. 11 Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN. 12 Research Group for Evolutionary Immunogenomics, Max Planck Institute for Evolutionary Biology, Plön, Germany; and. 13 Research Unit for Evolutionary Immunogenomics, Department of Biology, University of Hamburg, Hamburg, Germany.

Decade-long leukaemia remissions with persistence of CD4 + CAR T cells

Melenhorst JJ, et al.
February 2022
Authors and Affiliates
J Joseph Melenhorst #,1,2,3,4,5, Gregory M Chen #,6, Meng Wang #,7,8,9, David L Porter #,9,10, Changya Chen 11,12, McKensie A Collins 7,8,9,13, Peng Gao 11,12, Shovik Bandyopadhyay 13, Hongxing Sun 7,8,9, Ziran Zhao 7,8,9, Stefan Lundh 7,8,9, Iulian Pruteanu-Malinici 14, Christopher L Nobles 15, Sayantan Maji 7,8,9, Noelle V Frey 9, Saar I Gill 9, Lifeng Tian 7,9, Irina Kulikovskaya 7,8,9, Minnal Gupta 7,8,9, David E Ambrose 7,8,9, Megan M Davis 7,8,9, Joseph A Fraietta 7,8,9,15, Jennifer L Brogdon 14, Regina M Young 7,8,9, Anne Chew 7,8,9, Bruce L Levine 7,8,9, Donald L Siegel 7,8,16, Cécile Alanio 17,18,19, E John Wherry 17,18,19, Frederic D Bushman 15, Simon F Lacey 7,8,9, Kai Tan 20,21,22,23,24, Carl H June 25,26,27,28,29; 1 Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. mej@pennmedicine.upenn.edu. 2 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. mej@pennmedicine.upenn.edu. 3 Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. mej@pennmedicine.upenn.edu. 4 Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. mej@pennmedicine.upenn.edu. 5 Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia, USA. mej@pennmedicine.upenn.edu. 6 Graduate Group in Genomics and Computational Biology, University of Pennsylvania, Philadelphia, PA, USA. 7 Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 8 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 9 Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 10 Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 11 Center for Childhood Cancer Research, The Children's Hospital of Philadelphia, Philadelphia, PA, USA. 12 Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA. 13 Graduate Group in Cell & Molecular Biology, University of Pennsylvania, Philadelphia, PA, USA. 14 Novartis Institute for Biomedical Research, Cambridge, MA, USA. 15 Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 16 Department of Transfusion Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 17 Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 18 Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia, USA. 19 Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 20 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. tank1@chop.edu. 21 Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. tank1@chop.edu. 22 Graduate Group in Genomics and Computational Biology, University of Pennsylvania, Philadelphia, PA, USA. tank1@chop.edu. 23 Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA. tank1@chop.edu. 24 Graduate Group in Cell & Molecular Biology, University of Pennsylvania, Philadelphia, PA, USA. tank1@chop.edu. 25 Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. cjune@upenn.edu. 26 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. cjune@upenn.edu. 27 Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. cjune@upenn.edu. 28 Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. cjune@upenn.edu. 29 Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia, USA. cjune@upenn.edu. # Contributed equally.

Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer

Chun B, et al.
Journal for ImmunoTherapy of Cancer
February 2022
Authors and Affiliates
Brie Chun 1, Joanna Pucilowska 2, ShuChing Chang 3, Isaac Kim 1, Benjamin Nikitin 1, Yoshinobu Koguchi 1, William L Redmond 1, Brady Bernard 1 4, Venkatesh Rajamanickam 1,4, Nathan Polaske 5, Paul A Fields 5, Valerie Conrad 1, Mark Schmidt 1, Walter J Urba 1, Alison K Conlin 1, Heather L McArthur 6, David B Page 7; 1 Earle A Chiles Research Institute, Providence Cancer Institute, Portland, Oregon, USA. 2 Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA. 3 Medical Data Research Center, Providence St Joseph Health, Portland, Oregon, USA. 4 Computational Immuno-Oncology and Bioinformatics Core, Earle A. Chiles Research Institute, Portland, Oregon, USA. 5 Adaptive Biotechnologies Corp, Seattle, Washington, USA. 6 Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA. 7 Earle A Chiles Research Institute, Providence Cancer Institute, Portland, Oregon, USA david.page2@providence.org.

Multi-objective optimization reveals time- and dose-dependent inflammatory cytokine-mediated regulation of human stem cell derived T-cell development

Edgar JM, et al.
npj Regenerative Medicine
February 2022
immuneAccess
Authors and Affiliates
John M Edgar 1, Yale S Michaels 1, Peter W Zandstra 2,3; 1 School of Biomedical Engineering, University of British Columbia, Vancouver, BC, V6T 1Z3, Canada. 2 School of Biomedical Engineering, University of British Columbia, Vancouver, BC, V6T 1Z3, Canada. peter.zandstra@ubc.ca. 3 Michael Smith Laboratories, University of British Columbia, Vancouver, BC, V6T 1Z4, Canada. peter.zandstra@ubc.ca.

Identification of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer immunotherapy

Bonaventura P, et al.
Science Advances
February 2022
Authors and Affiliates
Paola Bonaventura 1,2, Vincent Alcazer 1, Virginie Mutez 3, Laurie Tonon 4, Juliette Martin 5, Nicolas Chuvin 3, Emilie Michel 3, Rasha E Boulos 3, Yann Estornes 3, Jenny Valladeau-Guilemond 1, Alain Viari 4, Qing Wang 6, Christophe Caux 1,2, Stéphane Depil 1,2,3,7; 1 Centre de Recherche en Cancérologie de Lyon (CRCL), UMR INSERM U1052 CNRS 5286, Lyon, France. 2 Centre Léon Bérard, Lyon, France. 3 ErVaccine Technologies, Lyon, France. 4 Synergie Lyon Cancer, Plateforme de bioinformatique « Gilles Thomas », Lyon, France. 5 CNRS-Institut de Biologie et Chimie des Protéines UMR 5086, Lyon, France. 6 Complete Omics, Baltimore, MD, USA. 7 Université Claude Bernard Lyon 1, Lyon, France.

T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma

Lozano AX, et al.
Nature Medicine
January 2022
Authors and Affiliates
Alexander X Lozano #,1,2, Aadel A Chaudhuri #,3,4,5,6, Aishwarya Nene #,7, Antonietta Bacchiocchi 8, Noah Earland 9, Matthew D Vesely 8, Abul Usmani 9, Brandon E Turner 10, Chloé B Steen 10,11, Bogdan A Luca 12, Ti Badri 13, Gunsagar S Gulati 10, Milad R Vahid 10, Farnaz Khameneh 10, Peter K Harris 9, David Y Chen 14,15, Kavita Dhodapkar 16, Mario Sznol 17,18, Ruth Halaban 8,18, Aaron M Newman #,19,20; 1 Department of Materials Science and Engineering, Stanford University, Stanford, CA, USA. 2 Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. 3 Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA. aadel@wustl.edu. 4 Department of Genetics, Washington University School of Medicine, St. Louis, MO, USA. aadel@wustl.edu. 5 Department of Computer Science & Engineering, Washington University, St. Louis, MO, USA. aadel@wustl.edu. 6 Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA. aadel@wustl.edu. 7 Yale School of Medicine, Yale University, New Haven, CT, USA. 8 Department of Dermatology, Yale University School of Medicine, New Haven, CT, USA. 9 Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA. 10 Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, USA. 11 Department of Biomedical Data Science, Stanford University, Stanford, CA, USA. 12 Stanford Center for Biomedical Informatics Research, Stanford University, Stanford, CA, USA. 13 Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA. 14 Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA. 15 Division of Dermatology, Washington University School of Medicine, St. Louis, MO, USA. 16 Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, GA, USA. 17 Department of Medicine, Division of Medical Oncology, Yale University School of Medicine, New Haven, CT, USA. 18 Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA. 19 Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, USA. amnewman@stanford.edu. 20 Department of Biomedical Data Science, Stanford University, Stanford, CA, USA. amnewman@stanford.edu. # Contributed equally.

A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab

Adusumilli PS, et al.
Cancer Discovery
January 2022
Authors and Affiliates
Prasad S Adusumilli 1,2,3, Marjorie G Zauderer 2,4, Isabelle Rivière 3,5, Stephen B Solomon 6, Valerie W Rusch 7, Roisin E O'Cearbhaill 2,8, Amy Zhu 7, Waseem Cheema 7, Navin K Chintala 7, Elizabeth Halton 2, John Pineda 2, Rocio Perez-Johnston 6, Kay See Tan 2,9, Bobby Daly 4, Jose A Araujo Filho 6, Daniel Ngai 7, Erin McGee 7, Alain Vincent 7, Claudia Diamonte 2, Jennifer L Sauter 10, Shanu Modi 2,11, Devanjan Sikder 5, Brigitte Senechal 5, Xiuyan Wang 5, William D Travis 10, Mithat Gönen 9, Charles M Rudin 4, Renier J Brentjens 2,3, David R Jones 7, Michel Sadelain 3; 1 Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. adusumip@mskcc.org. 2 Cellular Therapeutics Center, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 3 Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, New York. 4 Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 5 Michael G. Harris Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, New York. 6 Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York. 7 Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. 8 Gynecologic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 9 Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York. 10 Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. 11 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy

Smith EL, et al.
Cancer Immunology Research
January 2022
Authors and Affiliates
Eric L Smith 1,2, Sham Mailankody 3,2, Mette Staehr 3, Xiuyan Wang 4, Brigitte Senechal 4, Terence J Purdon 3, Anthony F Daniyan 3,5, Mark B Geyer 3,5, Aaron D Goldberg 5, Elena Mead 3,6, Bianca D Santomasso 3,7,8, Jonathan Landa 9, Andreas Rimner 10, Isabelle Riviere 4, Ola Landgren 2, Renier J Brentjens 1,5; 1 Cellular Therapeutics Center, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. smithe3@mskcc.org brentjer@mskcc.org. 2 Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 3 Cellular Therapeutics Center, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 4 Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, New York. 5 Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 6 Department of Anesthesiology and Critical Care Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 7 Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York. 8 Parker Institute for Cancer Immunotherapy, San Francisco, California. 9 Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York. 10 Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.

A Framework to Identify Antigen-Expanded T Cell Receptor Clusters Within Complex Repertoires

Ceglia V, et al.
Frontiers in Immunology
January 2022
Authors and Affiliates
Valentina Ceglia 1,2,3, Erin J Kelley 4, Annalee S Boyle 4, Sandra Zurawski 1,3, Heather L Mead 4, Caroline E Harms 4, Jean-Philippe Blanck 1, Anne-Laure Flamar 1,2,3, Jung Hwa Kirschman 4, Paul Ogongo 5, Joel D Ernst 5, Yves Levy 2,3, Gerard Zurawski 1,3, John A Altin 4; 1 Baylor Institute for Immunology Research, Dallas, TX, United States. 2 Université Paris-Est Créteil, Sciences de la Vie et de la Santé, Créteil, France. 3 Vaccine Research Institute, INSERM, Unité U955, Institut Mondor de Recherche Biomédicale, Créteil, France. 4 Translational Genomics Research Institute, Flagstaff, AZ, United States. 5 Department of Medicine, Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA, United States.

Modulation of the Human Pancreatic Ductal Adenocarcinoma Immune Microenvironment by Stereotactic Body Radiotherapy

Mills BN, et al.
Clinical Cancer Research
January 2022
Authors and Affiliates
Bradley N Mills 1, Haoming Qiu 2,3, Michael G Drage 4, Chunmo Chen 4, Jocelyn S Mathew 1, Jesse Garrett-Larsen 1, Jian Ye 1, Taylor P Uccello 5, Joseph D Murphy 5, Brian A Belt 1, Edith M Lord 3,5, Alan W Katz 2,3, David C Linehan 1,3, Scott A Gerber 6,3,5; 1 Department of Surgery, University of Rochester Medical Center, Rochester, New York. 2 Department of Radiation Oncology, University of Rochester Medical Center, Rochester, New York. 3 Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York. 4 Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York. 5 Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York. 6 Department of Surgery, University of Rochester Medical Center, Rochester, New York. scott_gerber@urmc.rochester.edu.